Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in IONS — Ionis Pharmaceuticals Inc

CIK 886982 NEW YORK, NY
Back to IONS Full portfolio

Position in IONS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$127,641,509
+$59,926,040 QoQ
Shares Held
1,699,847
+98.6% QoQ
Ownership
1.03%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 97.51430569927764.ToString("F0")% Shared 0.ToString("F0")% None 2.485694300722359.ToString("F0")%

Common Shares in IONS Over Time

Shares Held

Position Value (USD)

Derivatives in IONS

reported options exposure · as of Dec 31, 2025
CallValue
$13,155,993
CallShares
166,300
PutValue
$3,813,102
PutShares
48,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. IONS ranks #19 (1.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 2,417,875 $1,079,677,898
2 REGN
Regeneron Pharmaceuticals, Inc.
 1,300,558 $1,004,863,129
3 MRNA
Moderna, Inc.
 6,603,697 $335,467,805
4 ROIV
Roivant Sciences Ltd.
 11,111,591 $307,791,069
5 PRAX
Praxis Precision Medicines, Inc.
 710,734 $228,991,385
6 INCY
Incyte Corp
 2,351,221 $221,296,919
7 RVMD
Revolution Medicines, Inc.
 2,185,500 $212,539,874
8 RYTM
Rhythm Pharmaceuticals, Inc.
 1,965,432 $170,933,620

All Filings in IONS

Export CSV
42 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $127,641,509 1,699,847
2025-12-31 $3,813,102 48,200
2025-12-31 $13,155,993 166,300
2025-12-31 $67,715,469 855,966
2025-09-30 $10,879,346 166,300
2025-09-30 $50,868,628 777,570
2025-09-30 $10,545,704 161,200
2025-06-30 $30,736,408 777,940
2025-03-31 $19,686,467 652,518
2024-12-31 $1,748,000 50,000
2024-12-31 $1,748,000 50,000
2024-12-31 $13,222,151 378,208
2024-09-30 $2,003,000 50,000
2024-09-30 $9,442,542 235,710
2024-09-30 $2,003,000 50,000
2024-06-30 $15,647,015 328,305
2024-06-30 $2,073,210 43,500
2024-03-31 $520,200 12,000
2024-03-31 $8,686,471 200,380
2024-03-31 $520,200 12,000
2023-12-31 $1,517,700 30,000
2023-12-31 $19,294,113 381,382
2023-12-31 $1,517,700 30,000
2023-09-30 $15,323,831 337,827
2023-09-30 $403,704 8,900
2023-06-30 $7,728,903 188,372
2023-03-31 $15,085,781 422,098
2022-12-31 $34,839,462 922,411
2022-12-31 $944,250 25,000
2022-09-30 $57,081,689 1,290,565
2022-06-30 $38,568,323 1,041,824
2022-03-31 $35,348,234 954,326
2021-12-31 $17,932,337 589,298
2021-09-30 $20,185,578 601,836
2021-06-30 $27,102,422 679,429
2021-03-31 $33,491,152 744,910
2020-12-31 $59,030,813 1,044,054
2020-09-30 $27,998,346 590,060
2020-06-30 $45,032,350 763,778
2020-03-31 $945,600 20,000
2020-03-31 $945,600 20,000
2020-03-31 $34,029,779 719,750

Report a Problem

Category
Description
Email (optional, for follow-up)